Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanologica ABOSTO:NICA +5.10%45 Gross Margin % is 77.14% as of Mar. 2026, which is 27% above its 10-year median of 60.58. GuruFocus rates OSTO:NICA with a GF Score™ of 45/100 and a GF Value™ of kr4.24 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 732 Biotechnology companies, Nanologica AB ranks better than 51.23% on this metric.
The historical rank and industry rank for Nanologica AB's Gross Margin % or its related term are showing as below:
OSTO:NICA'
s Gross Margin % Range Over the Past 10 Years
Min: -5.27 Med: 60.58 Max: 248.73
Current: 61.8
During the past 12 years, the highestGross Margin % of Nanologica AB was 248.73%. The lowest was -5.27%. And the median was 60.58%.
OSTO:NICA's Gross Margin % is ranked better than 51.23% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs OSTO:NICA: 61.80
Nanologica AB had a gross margin of 77.14% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Nanologica AB was 0.00% per year.
Nanologica AB (OSTO:NICA) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nanologica AB had a gross margin of 77.14% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Nanologica AB Gross Margin % Related Terms
Nanologica AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Nanologica AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NICA vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Nanologica AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanologica AB Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanologica AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Nanologica AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nanologica AB (OSTO:NICA) has a Gross Margin % of 77.14% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Nanologica AB and its competitors. This is 27% above median its historical median of 60.58. According to the industry distribution chart, Nanologica AB ranks #357 out of 732 companies in the Biotechnology industry, placing it in the top 48.8%.
Is Nanologica AB's Gross Margin % too high?
Nanologica AB's current Gross Margin % of 77.14% is 27% above median its 10-year median of 60.58. The Biotechnology industry median Gross Margin % is 60.91. Nanologica AB's value of 77.14% is 26.7% above this industry median. Based on the distribution chart, Nanologica AB ranks #357 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nanologica AB has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanologica AB ranks #357 out of 732 companies for Gross Margin %. This puts Nanologica AB in the upper half of its industry. The industry median Gross Margin % is 60.91. Nanologica AB's value of 77.14% is 26.7% above this benchmark. While the company's 10-year median is 60.58 vs. the industry median of 60.91, Nanologica AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanologica AB's current Gross Margin % of 77.14% is 26.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Nanologica AB and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanologica AB's current Gross Margin % is 77.14%, which is 27% above median its own 10-year median of 60.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.24, compared to a current price of kr0.47 — trading 88.8% below its estimated fair value. The current Gross Margin % is 77.14%, which is 27% above median its 10-year median of 60.58 and 26.7% above the Biotechnology industry median of 60.91. Nanologica AB's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current Gross Margin % is 77.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanologica AB (OSTO:NICA) Overvalued in 2026?
Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued.
The current stock price of kr0.47 is trading 88.8% below its estimated GF Value™ of kr4.24.
GuruFocus considers Nanologica AB to be Possible Value Trap.
Key valuation signals for OSTO:NICA:
Gross Margin %: 77.14% (27% above median its 10-year median of 60.58)
GF Value™: kr4.24 vs. price of kr0.47 (88.8% below fair value)
Industry Position: 26.7% above the Biotechnology median (#357 of 732)
No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
45GF Score
Get the complete analysis for OSTO:NICA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NICA has been successfully added to your 
